Impact of Using Different SCORE Tables for Estimating Cardiovascular Risk

Brotons, Carlos; Moral, Irene; Soriano, Núria; Cuixart, Lluís; Osorio, Dimelza; Bottaro, David; Puig, Mireia; Joaniquet, Xavier; Marcos, A Caballero; Casasa, Albert

doi:10.1016/j.rec.2013.06.018

Cited by 8 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 arms: Experimental-EG ( n = 33) Supportive system to decision making Control-CG ( n = 44) Use of High intensity statins: EG: 74.6%/CG: 25.4% Statins + ezetimibe or niacin/laropiprant: GI: 32.4%/GC: 2.3% After 12 weeks: LDLc <70: 55% GI; 12.5% GC LDLc <100: 75% GI; 45.8% GC [ 80 ] N = 37 Statins: 100% Ezetimibe: 10.8% LDLc <130 md/dl: 43% [ 81 ] N = 222. LLT: 85% LDLc <100 mg/dl: 51.3% of high risk patients LDLc <70 mg/dl: 7.5% of high risk patients [ 77 ] N = 3716 (15.5% calibrated-SCORE >5) Statins: 25.3% Patients with SCORE between 5 and 10: LDLc <100 mg/dl: 10.61% SCORE >10 LDLc <70 mg/dl: 1.79% [ 1 ] N = 27,903 ( n = 9335 with dyslipidemia) High–very high risk: 11.3% males and 2.3% female LLT REGICOR >10: 50% males, 59% females LDLc <100 mg/dl in DM or high–very high risk: <3% LDLc <100 mg/dl in DM or <130 mg/dl in moderate to very high risk or <160 mg/dl in low risk): 46% males, 52% females [ 75 ] N = 2704 LLT: 1634 (60.4%) LDLc <100 mg/dl in DM or CVD; <130 mg/dl others: 930 (34.4%) LDLc <100 mg/dl: 34.7% DM; 34.2% CVD [ 82 ] N = 217 Ezetimibe (monotherapy): 42.4% Ezetimibe + statins: 43.3% LDLc <100 mg/dl or 70 mg/dl: 43.8% of high or very high risk patients [ 3 ] N = 11,544 Rate of awareness: 53.6% (53.5% males; 53.7% women) LLT treatment: 44.1% of patients aware of elevated LDLc 23.7% of all patients with elevated LDLc ...…”

Section: Resultsmentioning

confidence: 99%

Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain

et al. 2015

View full text Add to dashboard Cite

IntroductionCardiovascular diseases (CVDs) represent a major Public Health burden. High serum cholesterol levels have been linked to major CV risk. The objectives of this study were to review the epidemiology of hypercholesterolemia in high risk CV patients from Spain, by assessing its prevalence, the proportion of diagnosed patients undergoing pharmacological treatment and the degree of attained lipid control.MethodsA systematic literature review was carried out using Medline and two Spanish databases. Manuscripts containing information on hypercholesterolemia in several high CV risk groups [diabetes mellitus (DM), Systematic COronary Risk Evaluation (SCORE) risk >5, or documented CVD], published between January 2010 and October 2014, were included.ResultsOf the 1947 published references initially retrieved, a full-text review was done on 264 manuscripts and 120 were finally included. Prevalence of hypercholesterolemia ranged from 50 to 84% in diabetics, 30–60% in patients with DM or elevated SCORE risk, 64–74% with coronary heart disease, 40–70% in stroke patients, and 60–80% in those with peripheral artery disease. Despite the finding that most of them were on pharmacological treatment, acceptable control of serum lipids was very variable, ranging from 15% to 65%. Among those with heterozygous familial hypercholesterolemia, 95–100% received treatment but less than 50% achieved their therapeutic goals.ConclusionsAn elevated prevalence of hypercholesterolemia can be found in targeted groups at high CV risk. Although most patients are receiving pharmacological treatment, rates of lipid control continue to be low, both in primary and secondary prevention.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-015-0252-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The few existing population-based studies using SCORE are difficult to compare because of different national calibrations and exclusion criteria (e.g. in the Netherlands [ 7 ] individuals with a history of myocardial infarction were excluded, whereas in Switzerland [ 6 ] and in our study, individuals with a history of major CVD were not considered and other studies excluded individuals with diabetes [ 22 ], while we assigned them to the high risk group). Furthermore, studies using SCORE differ with regard to the definition of the high risk group.…”

Section: Discussionmentioning

confidence: 99%

Predicted 10-year risk of cardiovascular mortality in the 40 to 69 year old general population without cardiovascular diseases in Germany

et al. 2018

View full text Add to dashboard Cite

AimsTo estimate the 10-year risk of fatal cardiovascular disease (CVD) in the 40 to 69 year old general population in Germany stratified by sex and to analyze differences between socioeconomic status (SES), region and community size in individuals without CVD. The analysis is based on the newly recalibrated SCORE Deutschland risk charts and considered other comorbidities for the classification of the high CVD risk group according to the guidelines of the European Society of Cardiology. Methods and resultsIn 3,498 participants (40-69 years) from the German Health Examination Survey for Adults 2008-2011 (DEGS1) without a history of CVD (myocardial infarction, coronary heart disease, heart failure, stroke) we estimated the proportion with a low (SCORE <1%), moderate (SCORE 1-<5%) and high 10-year CVD mortality risk (SCORE !5% or diabetes, renal insufficiency, SBP/DPB !180/110 mmHg or cholesterol >8 mmol/l). The prevalence of low, moderate and high risk was 42.8%, 38.5% and 18.8% in men and 73.7%, 18.1% and 8.2% in women. The prevalence of high risk was significantly lower in women with a high compared to a low SES (3.3% vs. 11.2%) and in communities with !100.000 inhabitants compared to <20.000 inhabitants (5.4% vs.10.9%). There were no significant associations between predicted CVD mortality risk and SES or community size in men and regions in men and women. Among the high risk group, 58.2% of men and 9.8% of women had SCORE !5%, leaving the majority of women (60.1%) classified as high risks due to diabetes and SCORE <5%. ConclusionOur results suggest the persistence of socioeconomic disparities in predicted cardiovascular mortality in women and support the need of large-scale prevention efforts beyond individual lifestyle modification or treatment. Furthermore, the importance of additional comorbidities for the high risk group classification is highlighted.

show abstract

“…It showed that the percentage of patients at high or very high risk was 4.73% with the low-risk SCORE, and 15.44% with the calibrated SCORE (p < 0.01). The population-calibrated SCORE chart classifies a larger number of patients at high or very high risk, and its use would imply treating more patients with lipid-lowering medication [12].…”

Section: The Current Place Of the Score Risk Chartmentioning

confidence: 99%

Risk assessment according to the SCORE risk chart — from history, through present, to the future

2018

View full text Add to dashboard Cite

Karolina Adamkiewicz, MBBS BA (Hons) is a recent graduate of the King's College London School of Medical Education. She has previously completed her pre-clinical studies and BA at St. John's College, University of Cambridge. Currently, she is undertaking her Foundation training at the Royal London Hospital in the United Kingdom and has a keen interest in assessing cardiovascular risk and cardio-oncology. Doctor Adamkiewicz is focused on early risk stratification and identification of high-risk patients in non-specific populations. Her research projects are focused on cardiovascular risk.

show abstract

Impact of Using Different SCORE Tables for Estimating Cardiovascular Risk

Cited by 8 publications

References 27 publications

Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain

Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain

Predicted 10-year risk of cardiovascular mortality in the 40 to 69 year old general population without cardiovascular diseases in Germany

Risk assessment according to the SCORE risk chart — from history, through present, to the future

Contact Info

Product

Resources

About